Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease

Figure 4

Illustration to show the mechanism of 5-HT1D and 5-HT2AR in human T2DM. 5-HT1DR and 5-HT1AR messenger RNA expression was increased in human T2DM islets. The 5-HT2AR antagonist (sarpogrelate hydrochloride) markedly decreased the glycated hemoglobin A1c level. The expression of 5-HT1DR had a negative correlation with somatostatin (SST) and SST receptors (SSTR), whereas the expression of 5-HT2AR did not have any correlation with either SST or any of the SSTRs; this suggests that increased expression of HT1DR in human islet cells, as observed in T2DM islet cells, leads to decreased expression of SST and its receptors.